Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-10

FDA Approved: NPLATE — Supplemental Application (Amgen, Inc)

View source ↗

Summary

The FDA approved a supplemental application for NPLATE (romiplostim) from Amgen. This action updates the product’s labeling as described in the supplemental app…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nplate (romiplostim)

Snippet

SUPPL AP for NPLATE (ROMIPLOSTIM)